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a  b  s  t  r  a  c  t
Cancer  of  unknown  primary  (CUP)  is the ﬁnding  of  a  metastatic  cancerous  lesion  without  an  established
primary  source  localized  within  the  body.  CUP  can  be  of any  cancer  cell  type,  however,  adenocarcinoma
is  most  often  identiﬁed  by  histology.  Up to 5% of all malignant  diagnoses  are  classiﬁed  as  CUP. PET  is an
imaging  modality  often  utilized  to  distinguish  a primary  source  in the  setting  of  CUP,  yet often  a primary
is never  identiﬁed.  CUP  can  be  further  stratiﬁed  using  speciﬁc  qualiﬁers  as  favorable  and  unfavorable,
indicating  the  potential  therapeutic  response  to treatment  regimens.  Treatment  approach  to CUP  relies
heavily on the  cell  type  identiﬁed  by histology,  the  location  of  the lesion,  and the  amount  of spread  within
the  body.  In the  typical  setting  and  presentation,  per  current  literature,  CUP  arises  in the  7th  decade  of  life
in patients  with  multiple  comorbidities,  and  often  has  a poor  prognostic  value.  This  case  report  identiﬁes
an  atypical  presentation  of  CUP,  a 38-year-old  Caucasian  female  with  an  axillary  mobile  mass,  and  no
associated  systemic  symptoms.  Biopsy  of  the node  and  immunohistochemical  staining  showed  histology
consistent  with  metastatic  carcinoma.  Mammography,  MRI,  and  PET  scan  found  no  evidence  of tumor
primary  or  distant  metastasis.  Further  staining  conﬁrmed  metastatic  carcinoma  consistent  with  breast
origin,  without  an  established  breast  primary.  As in  this  case,  CUP  may  present  in an  atypical  manner,
warranting  a thorough  investigation  aiming  to  identify  the  tumor  primary  to  aid in identiﬁcation  of  a
proper  treatment  regimen  and  approach.
© 2016  The  Authors.  Published  by Elsevier  Ltd  on  behalf  of IJS  Publishing  Group  Ltd.  This  is an  open
he CCaccess  article  under  t
. Introduction
This case highlights metastatic carcinoma without a deﬁnitive
rimary source of tumor, better known as cancer of unknown pri-
ary (CUP). This is a diverse group of patients with the diagnosis
f metastatic malignancy, arising from any potential source in the
ody. CUP accounts for approximately 3–5% of all malignant diag-
oses [1–8]. Of the different types of cancers, adenocarcinoma of
arious differentiation is the most common histopathological sub-
ype [1,2]. The median age of diagnosis for all CUP, both men  and
omen, ranges from age 60–66 [2,3]. Even with exhaustive work
p, often the primary tumor is never found. Occult primary site may
emain unidentiﬁed in up to 70% of cases even at autopsy [4]. CUP
s also most often associated with a poor prognosis [5,6]. Generally,
he median survival can range from 11 weeks to 11 months, with a
ve-year survival rate of approximately 11% [3]. However, CUP can
e classiﬁed as either favorable, or unfavorable. Both Matias et al.
nd Ivica et al. report that CUP limited to a lymph node, specif-
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ically axillary in women, is a favorable prognostic subset with a
survival much greater than those CUPs classiﬁed as unfavorable.
The current standard of care for isolated axillary nodal metastasis
is mastectomy, or irradiation with chemotherapy [2,3].
2. Case
A 38-year-old Caucasian female presents with a 4-day history
of a mobile mass in her left axilla. She reports no systemic symp-
toms of fever, chills, night sweats or weight loss, nor any lumps
or masses felt on self-breast examination. Past medical history is
negative. Family history is signiﬁcant for neoplasm of the breast in
the maternal grandmother and ovarian cancer in a paternal aunt.
Clinically, breasts are small and symmetrical, and a nipple-areolar
complex with normal appearance. No palpable mass is assessed
in either breast, and no masses noted in the right axilla. A 2.5 cm
mobile left axillary node is palpated on examination.
Mammography was negative, and ultrasound showed a solid
mass in the left axilla. Excisional biopsy of the 3.5 × 3.0 × 2.0 cm
node was  performed and histology demonstrated highly pleomor-
phic, highly atypical cells with large nuclei and prominent nucleoli
with increased mitoses as well as necrosis (Figs. 1 and 2). Cells
demonstrated strong positivity for cytokeratin 7 and patchy pos-
roup Ltd. This is an open access article under the CC BY-NC-ND license (http://
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Fig. 1. Axillary node biopsy, magniﬁcation 10×.
Courtesy of Dr. Clinton McElroy, Department of Pathology, St. Francis Hospital,
Columbus, GA.
Fig. 2. Axillary node biopsy, magniﬁcation 40×.  Note the atypical, pleiomorphic
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ourtesy of Dr. Clinton McElroy, Department of Pathology, St. Francis Hospital,
olumbus, GA.
tivity for cytokeratin 5/6. Faint nuclear ER positivity was  shown
n approximately 1% of the cells. These ﬁndings suggest a proba-
le breast origin. Additional staining for mammaglobin, GCDFP-15,
AX-8, TTF-1, WT-1, S-100, cytokeratin 20, and progesterone recep-
or all resulted as negative. The tissue was conﬁrmed as metastatic
arcinoma consistent with breast primary. MRI  ﬁndings of the
reasts showed no evidence of carcinoma. Other than post-surgical
hanges in the left axilla, PET scan also showed no deﬁnitive evi-
ence of carcinoma or distant metastatic disease.
. Discussion
CUP is a unique class of metastatic cancer, seemingly oper-
ting by its own rules of growth and metastasis. Rather than
ollow the typical type 1 progression as developing a premalignant
esion transforming to primary malignant lesion and then exten-
ion via metastasis, rather, CUP operates as type 2 progression
hich is metastatic expansion without an established primary [2].
he parallel progression model describes early metastasis in the
evelopment of a metastatic process [2,4,6] and predicts greater
isparity between metastatic founders and primary tumor cellsFig. 3. Favorable and unfavorable subset classiﬁcation of CUP.
Credit: Pavlidis et al. [2].
than does linear progression [6], which is the development of
genetic alterations within a cell, progressing to tumor, and then
metastasis in a linear fashion. Vikesa et al. employed an extensive
workup investigating genes and transcript coding of CUP, ﬁnding
homologous repair networks suggesting chromosomal instability
(CIN). They conclude that CIN distinguishes CUP from metastases
of known origin. This instability of chromosomes renders CUP more
lethal and difﬁcult to treat as compared to cancer of known primary.
Diagnosis of CUP and proposed treatment rely heavily on iden-
tifying the type of cancer that is present, and also establishing its
origin, if possible. With the parallel progression theory in mind,
Bakhshayesharam et al. asserts that the primary lesion can be
nearly too small to detect on routine imaging, and warrant the
use of PET/CT. The advantage of this over anatomical imaging
reveals metabolic activity of structures, with whole body imag-
ing as the most useful tool to achieve the highest diagnostic yield
[4]. Bakhshayeshkaram et al. utilized PET/CT on 62 patients where
CT failed to identify a tumor primary in the setting of CUP. Of
those 62 patients, PET/CT only identiﬁed a primary in 29 cases
(48.8%). As with the speciﬁc patient highlighted in this case report,
although a very useful imaging modality, PET did fail to identify
a tumor primary for our patient. With ill-deﬁnitive imaging ﬁnd-
ings and ambiguous immunohistochemistry (IHC), are there other
options to consider for diagnosis? Molecular proﬁling, also referred
to as gene expression proﬁling (GEP), is a potential alternative.
The rationale for studying molecular assays that deﬁne the loca-
tion of origin in CUP is that cancers of different sites have speciﬁc
genetic expression proﬁles that match their normal counterpart
[5]. Per investigation by Green, the accuracy of GEP  was signiﬁ-
cantly greater for poorly differentiated carcinomas (GEP 91%, IHC
71%, p = 0.023), and for cases that required 6 or more IHC stains, or
a second requested round of staining [7]. The recommendation is
that proﬁling assays be used in conjunction with IHC assay and clin-
ical presentation [5]. However, Green asserts that even with GEP,
up to 40% of CUPs may  remain without an identiﬁed primary site,
and further research on the topic is warranted.
Treatment approach of CUP depends primarily on the type of
cancer, location, degree of involvement and spread, and likeli-
hood of therapeutic response. This speciﬁc case, showing isolated
axillary nodal metastasis, is classiﬁed as a favorable outcome sub-
set of CUP (Fig. 3). This classiﬁcation is generated by oncological
stratiﬁcation based on clinical presentation, host factors, tumor
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istology, the amount and location of metastatic sites, and sen-
itivity to chemoradiation [3]. Per current research, the proposed
reatment for isolated axillary metastasis with the best outcome
s nodal dissection, mastectomy or breast irradiation and adju-
ant chemo/hormonotherapy [2,3]. Survival is said to be longer
n patients who received bilateral breast radiotherapy along with
djuvant systemic treatment [2]. Treatment approach selected for
his patient is chemotherapy alone, without radiation or mastec-
omy at this time. This was decided based upon a second PET scan
ailing to show tumor or metastases, and BRCA testing with a neg-
tive result.
Potential and projected outcomes for patients diagnosed with
UP is a very important topic. Schaffer et al. established a retrospec-
ive cohort study, utilizing members of the Australian Government
epartment of Veteran’s Affairs. Patients with CUP totaled 252,
ith a median age of 84 at diagnosis, and 980 patients with cancer
f known primary, with median age of 83 at diagnosis. According
o Schaffer et al., median survival at two years for CUP was 10%,
nd 33% for cancer of known primary. It was also established that
UP patients did have more hospitalizations and more comorbidi-
ies prior to diagnosis, compared to those patients with cancer of
nown primary origin [8]. Findings by Schaffer et al. do support the
bservation that CUP is a more advanced and aggressive metastatic
isease at presentation, and with a poorer prognosis and outcome.
. Conclusion
This case report has identiﬁed and presented a 38-year-old Cau-
asian female patient with an enlarged axillary node found to be
etastatic carcinoma of breast origin without an identiﬁed breast
umor primary. This patient does not ﬁt the typical proﬁle of CUP,
s she is much younger than the median age of diagnosis, and also
oes not have a history of extensive comorbidities. As previously
iscussed, given the presentation of isolated axillary node metas-
asis, this patient has a more favorable prognosis comparatively to
hose categorized as unfavorable. Treatment for this patient was
elected as chemotherapy alone, without mastectomy or combina-
ion irradiation and chemotherapy, given the inability to ﬁnd tumor
etastases via PET scanning, and negative BRCA results. It is chal-
enging to predict a prognosis speciﬁc to this patient or stratify
he risk of relapse as this case is certainly unique compared with
urrent research and presentation. We  will continue to follow and
onitor this patient.
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